Co-assembly of oligo-urethane nanoparticles with defined lipid additives to tailor RNA delivery into cells
Acta Biomaterialia · 2025
DOI: 10.1016/j.actbio.2025.06.017 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Biomaterialia, 2025. Verfasst von Suja Shrestha und 9 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Dentistry, University of Toronto, Toronto, Ontario M5G 1G6, Canada; Translational Biology and Engineering Program and Ted Rogers Centre fo…. Hauptthemen laut MEDLINE: Nanoparticles, Lipids, Urethane, Gene Transfer Techniques. Die Arbeit nennt 45 Literaturangaben. Gefördert von: The Hospital for Sick Children, University of Toronto.
Abstract (Originalsprache)
Developing safe and effective biomaterials to deliver RNA into cells has grown in importance over recent years and has enabled the clinical translation of several gene therapies. Self-assembled oligo-urethane nanoparticles (PNPs) have several advantageous properties, such as (1) mitigating immune cell response in vivo, (2) low cytotoxicity in a broad range of cells, and (3) capable of delivering oligonucleotides or proteins into cells. Here, we were interested in defining unique configurations of PNPs to assess their relative cytotoxicity to human cells, comparing them to a popular commercial lipid system MessengerMax, as some cationic lipids have been found to have associated toxicity, instigating the search for less toxic counterparts. This was then followed by demonstrating the ability of enhanced green fluorescent protein (EGFP) mRNA to be loaded onto the PNPs, and to establish methods to enable the efficient transgene expression in a number of cell types, including Caco-2 and C2C12 cells which are known to be difficult-to-transfect cells. The addition of small amounts of PEGylated lipid to PNP significantly increased EGFP expression in HEK293T cells, Caco-2 cells and C2C12 cells at an effective mRNA/PNPs ratio (wt/wt) of 1:40, while the addition of the ionizable cationic lipid, significantly increased EGFP expression in C2C12 cells and differentiated C2C12 cells (myofibers) at mRNA/PNPs ratio (wt/wt) of 1:125, while keeping PNPs mass constant to 62.5 μg and changing the mRNA mass. Our study demonstrated that lipid-assisted, PNP-mediated mRNA delivery achieved a high transfection efficiency in terminally differentiated myofibers, paving the way for potential innovative therapeutics, e.g. targeted to muscular dystrophies. STATEMENT OF SIGNIFICANCE: There are reports of diverse delivery agents for RNA, but there is still unmet need for more versatile, and safe delivery vehicles. In this study we demonstrated that when compared to MessengerMax (a lipid-based mRNA transfection reagent), self-assembled oligo-urethane nanoparticle (PNP) showed favorable cell viability. The scope of PNP as a RNA delivery vehicle was extended beyond HEK293T cells by showing transfections into a number of cell types. The addition of select lipids to PNPs, significantly increased EGFP expression in difficult-to-transfect cells: Caco-2 (2.9-fold), C2C12 (1.4-fold) and differentiated C2C12 (1.28-fold) cells when compared to PNPs. These findings indicate that select lipid incorporation on PNPs provide a promising strategy to improve the efficacy of RNA therapeutics for diseases in clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Dentistry, University of Toronto, Toronto, Ontario M5G 1G6, Canada; Translational Biology and Engineering Program and Ted Rogers Centre for Heart Research, Toronto, Ontario M5G 1M1, Canada.
- Translational Biology and Engineering Program and Ted Rogers Centre for Heart Research, Toronto, Ontario M5G 1M1, Canada.
- Translational Biology and Engineering Program and Ted Rogers Centre for Heart Research, Toronto, Ontario M5G 1M1, Canada; Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada.
- Genetics & Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada; Department of Molecular & Medical Genetics and Paediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontar…
- Department of Molecular & Medical Genetics and Paediatrics, Faculty of Medicine, University of Toronto, Toronto, Ontario M5S 1A8, Canada; Division of Clinical and Metabolic Genetics, The Hospital for Sick Children, Toro…
- Department of Physiology, University of Toronto, Toronto, Ontario M5S 1A8, Canada; Genetics & Genome Biology Program, The Hospital for Sick Children, Toronto, Ontario M5G 0A4, Canada.
Förderung
- The Hospital for Sick Children
- University of Toronto
Zitieren
APA
Shrestha, S., Yan, E., Yang, B., Blundell, A., Teng, A. C. T., Marks, R. M., Cohn, R., Ivakine, E., Gramolini, A. O., & Santerre, J. P. (2025). Co-assembly of oligo-urethane nanoparticles with defined lipid additives to tailor RNA delivery into cells. Acta Biomaterialia. https://doi.org/10.1016/j.actbio.2025.06.017
Vancouver
Shrestha S, Yan E, Yang B, Blundell A, Teng ACT, Marks RM, et al. Co-assembly of oligo-urethane nanoparticles with defined lipid additives to tailor RNA delivery into cells. Acta Biomaterialia. 2025. doi:10.1016/j.actbio.2025.06.017
BibTeX
@article{Shrestha2025,
author = {Shrestha, Suja and Yan, Elaine and Yang, Beining and Blundell, Aled and Teng, Allen C T and Marks, Ryan M and Cohn, Ronald and Ivakine, Evgueni and Gramolini, Anthony O and Santerre, J Paul},
title = {Co-assembly of oligo-urethane nanoparticles with defined lipid additives to tailor RNA delivery into cells},
journal = {Acta Biomaterialia},
year = {2025},
doi = {10.1016/j.actbio.2025.06.017}
}
EUVIMED